Neuraminic (sialic) acid concentrations in serum from normal and sickle cell (HbSS) subjects were determined for discrete age groups from childhood through adolescence. Values in sickle cell disease were consistently lower over the entire age range. We further investigated the effect of exogenous sialic acid on the rate of sickling reversion of HbSS erythrocytes and demonstrated that this compound in millimole per liter concentrations could revert pre-sickled erythrocytes to their normal morphology in a concentration-dependent manner. When subjected to partial de-sialation with sialidase (EC 3.2.1.18), the HbSS erythrocytes not only sickled faster upon deoxygenation, they also reverted more slowly on treatment with phenylalanine (a more efficient anti-sickling agent than sialic acid) than did untreated cells. We conclude that, in sickle cell disease, erythrocyte sialic acid content could play a significant role, not only in the control of the sickling rate in vivo, but also, after sickling has occurred, in the rate of recovery from a sickling crisis. ATPase pump, result from a defective erythrocyte membrane (4). Sialic acid, a major component of membrane glycoprotein, is important in maintenance of cellular integrity. Recognition of this has lead in recent years to the investigation of its involvement in several diseases, including SCD and thalassemia (5, 6). These studies have shown that, compared with normal individuals, there is marked decrease in sialic acid content in thalassemia. But not much information is available on the distribution by age on the possible physiological relationship between sialic acid in plasma and SCD. Our objective here was to estimate the plasma content of sialic acid in SCD and to assess its possible role in the etiology of the disease. 
Materials and Methods

Blood Collection
Venous blood was sampled from 66 subjects of both sexes, whose homozygous sickle cell condition (HbSS) was confinned by electrophoresis of the hemoglobin on cellulose acetate. Blood was also collected from 30 normal subjects of HbAA genotype and of both sexes. Both groups (sicklers and non-sicklers) fell within the same age range, 2-28 y, and the consent of all subjects (including the parents of minors) was obtained before blood was collected.
For studies of sialic acid we used serum. For other studies that required uncoagulated blood, we used Na2EDTA as the anticoagulant. Preliminary screening eliminated from our studies those sicklers who had had a blood transfusion not later than three months before this study began.
The sicklers were, however, either in crisis or in the steady state at the time they visited our clinics for blood collection. All serum samples were stored at -20 #{176}C until analysis.
Reagents
Commercial kit for sialic acid. This was purchased from Boehringer Mannheim GmbH, Mannheim, F.R.G. The kit was used, with negligible modification, as directed by the suppliers.
Sialidase (EC 32.1 .18). The lyophilized enzyme (as purchased, unstandardized for specific activity) was also from Boehringer Mannheim. A stock solution of the sialidase was prepared, to give a concentration of 1 mg of lyophilized enzyme per milliliter in Tris acetate buffer, 150 mmol/L (pH 6.5), as adapted from McBride and Rodgerson (7), and 100-L portions were stored at -20 #{176}C. The Tris buffer was also used as the assay buffer when we determined the sialidase activity of the lyophilized enzyme.
Sialic acid. This was of analytical grade and was purchased from Sigma Chemical Co., St. Louis, MO 63178.
Phosphate-buffered saline (PBS). PBS, 200 mmol of phosphate per liter, pH 7.5, was prepared in distilled water as previously described (8), except that no polyethylene glycol was included.
Buffers stored at 4#{176}C remained stable for at least two months.
Procedure
Standardization of the sialidase. We diluted our stock sialidase solution (1 g/L in Ti-is buffer, pH 6.5) with the same buffer to obtain enzyme concentrations ranging from 0.1 to 0.4 ing/mL. in such a way as to nearly fill up the tube, but allowing a little air space. The tube was capped tightly and made further air-tight by sealing with paraffin wax. Each tube and its contents were mixed gently by rolling for about 1 h, at the end of which at least 45% of the cells had sickled.
Eiythrocytes
Reversion of sickled cells with sialic acid. To estimate the ability of sialic acid to reverse pre-siclded
HbSS erythrocytes, we incorporated exogenous sialic acid into the following assay system: We mixed together, in an LP3 disposable 2.5-mL plastic tube, 1.9 mL of blood whose erythrocytes were about 60 to 70% pre-sickled in sodium metabisullite and 0.1 mL of stock solution of sialic acid prepared with PBS. The tube was tightly capped with its plastic cap, the contents were mixed manually, and a drop of the mixture was quickly withdrawn at various intervals and placed on a microscope slide; the percentage of sickled cells was estimated by counting at least 500 erythrocytes.
A control experiment was always included, in which an equivalent volume of PBS replaced the sialic acid.
Sickling rate of sialidase-treated HbSS erythrocytes. We incubated 200 L of sialidase (3.2 U) and 800 L of blood (10% packed cell volume) in 150 mmol/L Tris acetate buffer, pH 6.5, at 37 #{176}C in Luckham LP3 disposable plastic tubes for precisely 30 mm. We stopped the reaction by adding 2.0 mL of a 20 g/L solution of sodium metabisulfite, which also initiated the sickling of the sialidase-treated erythrocytes.
While the tube was being constantly rotated to mix its contents, a drop of the mixture was withdrawn at intervals for microscopic estimation of the percentage of sickled cells. A control experiment was set up in parallel, in which the Tris acetate buffer replaced the enzyme.
Phenylal.anine reversion of sickling in sialidase-treated HbSS erythrocytes.
We first pre-sickled sialidase-treated Figure 1 shows sialic acid values for both normal and sickle cell serum samples.
Results
In comparison with normal subjects, lower concentrations of sialic acid were observed in the sickle cell samples from all the age groups. Except for the age group 0 to 5 y, where the difference was not significant (P >0.2), the difference was highly significant (0.05< P >0.01). Additionally, there was a progressive increase in serum sialic acid with age, rapid initially but leveling out from about the age of 15 y upwards (Figure 1) .
Although information
regarding the sialic acid content of erythrocyte membrane in SCD is available in the literature (5, 6), we could not find similar information for serum or plasma, especially with regard to its variation with age, in this disease.
Effect of sialic acid on sickling. Exogenous sialic acid was shown to reverse pre-sickled erythrocytes (Figure 2 ), and this process was shown to be concentration dependent. For example, we observed that sialic acid at 8 mmol/L reversed about 50% of the sickled cells to their normal shape within 15 mm in vitro, whereas at a 2 mmol/L concentration, only about 10% of sickled cells reverted during about the same interval.
The effect of sialidase treatment on sickling rate. Figure 3 shows the sickling rates of enzyme-treated and untreated HbSS erythrocytes.
It is evident that the sickling rate was consistently and significantly slower in the untreated (control) erythrocytes. is age-dependent in SCD, but proteolytic changes do occur in mammalian erythrocytes at various stages of maturation (12).
We observed the least sialic acid changes between normals and sicklers at ages 0 to 5 y. SCD does not manifest very early in life because of certain factors such as the generally high concentration of fetal hemoglobin in the young (13). It is, however, uncertain whether the nearnormal sialic acid in this age range plays any stabilizing role in sickle cell crisis.
Sialic acid and the sickling phenomenon. Sialic acids are basically charged sugars of various molecular sizes and complexity. Perhaps they exert their anti-sickling role in a manner similar to that reported for other sugars (14). The sialic acid we used in this work is a fairly small molecule (Mr 309). Possibly it exerts its anti-sickling action by gaining access into the erythrocyte.
Other modes of action are also possible, such as interacting with the membrane to effect an internal conformational change favorable to the anti-sickling process. Interestingly, the mean serum sialic acid concentrations in all ages we studied fell just outside the effective anti-sickling threshold of about 3 to 4 mmol/L observed in vitro. Therefore, plasma sialic acid in SCD would be expected to contribute little to the anti-sickling process in this disease. Clearly, in molar terms, sialic acid is far lesseffective as an anti-sickling agent than is Phe or uric acid (15) . Its smaller concentration in SCD is certainly a disadvantage to the patient. Sialic acid-deficient HbSS erythrocytes, which we produced by partly digesting them with sialidase, sickled more rapidly, but reverted more slowly, than untreated cells. In vitro, we were then able to mimic the effect of irreversible sickle cells. Information is not readily available in the literature about sialic acid concentrations in erythrocyte membranes in reversible and irreversible sickle cells. However, cells with membranes that are more deficient in sialic acid should be expected to be removed faster from circulation by the reticuloendothelial system, e.g., by the spleen. sickling rate in 20 mm was about 20% (± 3%) and 13% (± 4%) for enzyme-treated and untreated cells, respectively. This difference in sickling rate is highly significant (P
<0.01).
Sickling reversion of sialidase -treated erythrocytes. should be expected to repel one another less, clump together more, and compete more avidly for the already decreased oxygen in the microvasculature.
The slow reversion rate of sialic acid-deficient HbSS erythrocytes, when challenged with a sickling reversal agent such as Phe, should be considered an important factor in the therapeutic management of SCD. if this in vitro phenomenon can be reproduced in vivo, it could imply that erythrocyte sialic acid content in SCD would play an important role in the rate of recovery from a sickling crisis, as well as in the severity of such crisis.
We observed a higher (by about 50%) sialic acid concentration in serum from the non-sickler, especially in adulthood, when compared with some values in the literature. The reason for this difference in value is unclear. However, it is well documented that sialic acid concentrations are increased in various pathological conditions, including inflammations and general infections (16, 17) . No definite conclusion based on pathology can be drawn for the Nigerian populace until sialic acid values in serum from discrete age groups have been measured in a much larger population.
